Kuckelman, Novos senior vice president and general counsel, said Novo welcomes competition grounded in science, but it cannot stand by as advertising continues to withhold the information patients need, saying Lillys misleading ads leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true. In a statement earlier this week, Lilly said it stood by its ads, calling them "truthful," "transparent" and grounded in the most direct scientific evidence available - exactly what patients deserve. What Did Novo Nordisk Allege In Its Lawsuit
Merkbaar betere vitaliteit, betere vacht en huidconditie
Redefining GLP-1 Weight Loss Success Every members weight loss journey is highly complex and personal
Saffron extract is not a direct GLP-1 receptor agonist like medications such as semaglutide
Animal studies, including rabbit models of segmental bone loss, have demonstrated improved regenerative outcomes following peptide administration
The Regulatory Landscape in 2026 If you're reading this in 2026, you know the peptide space is at a pivotal moment
